Table 1.
Characteristics of patients recruited into analysis.
| Characteristic | Non-IBD Control | CD | p-Value CD vs. Non-IBD |
|---|---|---|---|
| Number of patients | 25 | 30 | |
| Gender, n (%) | |||
| Male | 11 (44) | 19 (63) | 0.11 |
| Female | 14 (56) | 11 (37) | |
| Median age (range) | 61 (25–80) | 49 (20–71) | 0.0002 |
| Race, n (%) | |||
| Caucasian | 17 (68) | 24 (80) | 0.36 |
| African American | 8 (32) | 3 (10) | 0.09 |
| Asian | 0 | 1 (3) | 0.99 |
| Hispanic | 0 | 2 (6) | 0.50 |
| Harvey Bradshaw Index Score | N/A | 0–22 | |
| IBD treatment at biopsy, n (%) | |||
| 5-ASA | 5 (17) | ||
| 6-MP/AZA/MTX | 6 (20) | ||
| Biologics a | 17 (56) | ||
| Steroids | 6 (20) | ||
| Antibiotics | 0 | ||
| NSAIDS | 4 (13) | ||
| No treatment | 5 (17) | ||
| Tobacco use b, n (%) | |||
| Smoker | 1 (4) | 3 (10) | 0.99 |
| Non-smoker | 17 (68) | 26 (87) | 0.07 |
| Other conditions, n (%) | |||
| Coronary artery disease | 2 (8) | 1 (3) | 0.59 |
| Diabetes mellitus | 3 (12) | 4 (13) | 0.99 |
| Hypertension | 10 (40) | 9 (30) | 0.78 |
| COPD | 1 (4) | 0 | 0.45 |
| Congestive heart failure | 2 (8) | 1 (3) | 0.59 |
| Cerebrovascular event | 0 | 3 (10) | 0.24 |
| Peripheral vascular dis. | 1 (4) | 0 | 0.45 |
| Ankylosing spondylitis | 0 | 4 (13) | 0.12 |
| Rheumatoid Arthritis | 2 (8) | 1 (3) | 0.59 |
| Psoriasis | 0 | 1 (3) | 0.99 |
| Spondyloarthropathy | 0 | 2 (7) | 0.49 |
a Infliximab, adalimumab, vedolizumab, ustekinimab. b Missing data from 7 non-IBD and 1 CD patients. CD, Crohn’s disease; 5-ASA, 5-aminosalicylic acid; 6-MP, 6-mercaptopurin; AZA, Azathioprine; MTX, Methotrexate; NSAIDs, nonsteroidal anti-inflammatory drugs; COPD, chronic obstructive pulmonary disease.